NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Fundamental Analysis
Europe - Euronext Oslo - OSL:NYKD - NO0010714785 - Common Stock
2.296 NOK
+0.04 (+1.59%)
Taking everything into account, NYKD scores 3 out of 10 in our fundamental rating. NYKD was compared to 82 industry peers in the Biotechnology industry. The financial health of NYKD is average, but there are quite some concerns on its profitability. NYKD is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NYKD has reported negative net income.
NYKD had a negative operating cash flow in the past year.
In the past 5 years NYKD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NYKD reported negative operating cash flow in multiple years.
1.2 Ratios
NYKD's Return On Assets of -10.38% is fine compared to the rest of the industry. NYKD outperforms 60.98% of its industry peers.
NYKD has a better Return On Equity (-11.11%) than 65.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.38% | ||
| ROE | -11.11% | ||
| ROIC | N/A |
ROA(3y)-20.54%
ROA(5y)-0.01%
ROE(3y)-25.46%
ROE(5y)0.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NYKD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NYKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
NYKD has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, NYKD has more shares outstanding
The debt/assets ratio for NYKD has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 6.77 indicates that NYKD is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.77, NYKD belongs to the top of the industry, outperforming 80.49% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that NYKD is not too dependend on debt financing.
NYKD has a better Debt to Equity ratio (0.02) than 69.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.77 |
ROIC/WACCN/A
WACC8.53%
2.3 Liquidity
A Current Ratio of 17.14 indicates that NYKD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 17.14, NYKD belongs to the top of the industry, outperforming 97.56% of the companies in the same industry.
A Quick Ratio of 17.14 indicates that NYKD has no problem at all paying its short term obligations.
NYKD has a better Quick ratio (17.14) than 97.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.14 | ||
| Quick Ratio | 17.14 |
3. Growth
3.1 Past
NYKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 90.47%, which is quite impressive.
Looking at the last year, NYKD shows a very strong growth in Revenue. The Revenue has grown by 72.62%.
Measured over the past years, NYKD shows a very negative growth in Revenue. The Revenue has been decreasing by -36.54% on average per year.
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)72.62%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
The Earnings Per Share is expected to decrease by -66.63% on average over the next years. This is quite bad
The Revenue is expected to grow by 184.95% on average over the next years. This is a very strong growth
EPS Next Y74.49%
EPS Next 2Y14.88%
EPS Next 3Y16.34%
EPS Next 5Y-66.63%
Revenue Next Year-72.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NYKD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYKD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NYKD's earnings are expected to grow with 16.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.88%
EPS Next 3Y16.34%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 44.05%, NYKD is a good candidate for dividend investing.
NYKD's Dividend Yield is rather good when compared to the industry average which is at 0.80. NYKD pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 1.87, NYKD pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 44.05% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y14.88%
EPS Next 3Y16.34%
OSL:NYKD (12/22/2025, 3:44:46 PM)
2.296
+0.04 (+1.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners15.07%
Inst Owner ChangeN/A
Ins Owners0.96%
Ins Owner ChangeN/A
Market Cap749.76M
Revenue(TTM)6.77M
Net Income(TTM)-11.00M
Analysts42.22
Price Target5.46 (137.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 44.05% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.88%
PT rev (3m)3.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-50%
EPS NY rev (3m)57.14%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.88 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.74 | ||
| P/tB | 0.74 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.09
OCFYN/A
SpS0.21
BVpS3.1
TBVpS3.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.38% | ||
| ROE | -11.11% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-20.54%
ROA(5y)-0.01%
ROE(3y)-25.46%
ROE(5y)0.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.31% | ||
| Cap/Sales | 1.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.14 | ||
| Quick Ratio | 17.14 | ||
| Altman-Z | 6.77 |
F-Score5
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)80.07%
Cap/Depr(5y)78.31%
Cap/Sales(3y)17.62%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y74.49%
EPS Next 2Y14.88%
EPS Next 3Y16.34%
EPS Next 5Y-66.63%
Revenue 1Y (TTM)72.62%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-72.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%
EBIT growth 1Y55.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.75%
EBIT Next 3Y17.92%
EBIT Next 5Y-60.17%
FCF growth 1Y44.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.38%
OCF growth 3YN/A
OCF growth 5YN/A
NYKODE THERAPEUTICS ASA / NYKD.OL FAQ
What is the ChartMill fundamental rating of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?
ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL.
What is the valuation status for NYKD stock?
ChartMill assigns a valuation rating of 0 / 10 to NYKODE THERAPEUTICS ASA (NYKD.OL). This can be considered as Overvalued.
What is the profitability of NYKD stock?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a profitability rating of 1 / 10.
What is the financial health of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?
The financial health rating of NYKODE THERAPEUTICS ASA (NYKD.OL) is 6 / 10.